Earnings call transcript: IRIDEX Q3 2026 misses estimates as shares sink 25%
IRIDEX reported a wider-than-expected third-quarter loss and weaker revenue for Q3 2026, sending its shares down 25.4% in after-hours trading to $0.5221. The company posted an adjusted loss of $0.08 a share, compared with analysts’ estimate for a loss of $0.02, while revenue came in at $10.2 million versus expectations of $12.98 million. The results reflected sharp weakness in international retina sales, partly offset by stronger U.S. glaucoma performance and a steep improvement in gross margin.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.